Teva hikes prices of 20 drugs but not Copaxone - (Globes via NewsPoints Desk)

  • According to a survey by UBS healthcare analyst Marc Goodman, while Teva raised the prices of 20 drugs, the drugmaker did not increase the price of its multiple sclerosis treatment Copaxone as it faces generic competition from Mylan, Globes reported Tuesday.

  • Teva's price increases ranged between 2.3 percent and 9.4 percent, with the price of Amrix for the treatment of muscle pains increased by 9.4 percent and the price of the company's Parkinson's treatment Azilect raised 3 percent, after being increased by 9.4 percent last year and by 9.9 percent in 2016.

  • Meanwhile, respiratory drugs Qnasl and AirDuo RespiClick were raised by 8 percent and Qvar's price was increased by 9 percent.

  • In the oncological sector, the price of Treanda was increased by 6 percent and Synribo by 4.5 percent.

  • Teva increased the price of Copaxone by 7.9 percent last January and the US Congress recently presented data showing that the price had risen 1002 percent since the drug's launch in 1996. 

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.